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In response to the letter from Dr. Nuggehally R. Srinivas
titled ‘‘Comment on: ‘‘Pharmacokinetics and Pharmacoki-
netic/Pharmacodynamic Modeling of Filgotinib
(GLPG0634), a Selective JAK1 Inhibitor, in Support of
Phase IIB Dose Selection’’’’ (Srinivas NR 2015)
We thank Dr. Srinivas for his interest in the publication
and his constructive comments. We welcome the oppor-
tunity to clarify and discuss additional information about
filgotinib and its active metabolite.
The in vitro characterization of the main enzyme(s) in-
volved in the metabolism of filgotinib revealed that car-
boxylesterase 2 (CES2) is the main isoform involved in the
metabolism of filgotinib and in the formation of its major
active metabolite. Of interest, some saturation of human
CES2 was noticed in vitro, which was partially compen-
sated by human carboxylesterase 1 (CES1) forming the
active metabolite. These data indicate that even in the case
of complete inhibition and/or saturation of CES2 in
humans, the metabolic elimination of filgotinib would not
be blocked and liver CES1 could also form the active
metabolite. Of note, as an integral part of the validation of
the bioanalytical method, we have shown that filgotinib is
stable in whole blood as well as in plasma. These data
suggest that blood carboxylesterases are not involved in the
formation of the active metabolite. Nevertheless, although
the plateauing effect in plasma curves of the metabolite
could be due to conversion of circulating filgotinib, which
escaped the first-pass effect, it could also result from slow
elimination of the metabolite itself.
As pointed out by Dr. Srinivas, the metabolite/filgotinib
area under the plasma-concentration curve ratio tends to
decrease with increasing doses, which could reflect the
effect of saturation of the pre-systemic conversion of fil-
gotinib to the active metabolite. However, in the case of
saturable pre-systemic conversion, one would have
expected the maximum plasma concentration to also be
affected. However, over the dose range tested, the
metabolite/filgotinib ratio estimated for the maximum
plasma concentration was found to be relatively constant
after single (2.9 and 2.0) and repeated doses (twice daily:
5.8–7.2 and once daily: 3.0–2.0).
With regard to the simulated JAK1 inhibition, similar
responses were obtained after 100 mg twice daily and
200 mg once daily (78.5 vs. 77.6 %). At these two dosing
regimens, the effective exposure (sum of parent and
metabolite exposure taking into account the lower potency
for the metabolite) over the dosing interval is about two-
fold higher after 200 mg once daily vs. 100 mg twice daily.
This suggests that the average concentration is similar for
these two treatment regimens, and is predictive of the mean
pSTAT1 inhibition.
To clarify, the concept of a saturable pre-systemic
conversion of filgotinib to its active metabolite was
investigated in the population pharmacokinetic analysis
based on two additional models:
• Publication model: dose-independent pre-systemic fil-
gotinib-metabolite conversion and dose-dependent
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‘‘secondary pathway of elimination’’ of filgotinib
(OFV: 23504).
• Alternative 1: saturation of pre-systemic conversion of
filgotinib to metabolite and dose-dependent ‘‘secondary
pathway of elimination’’ of filgotinib (OFV: 23490).
• Alternative 2: saturation of pre-systemic conversion of
filgotinib to metabolite with no ‘‘secondary pathway of
elimination’’ of filgotinib (OFV: 23537).
Including the dose-dependent pre-systemic conversion
led to a statistically significant improvement in NONMEM
OFV of -14, corresponding to p = 0.0002 (alternative 1
compared with the publication model). However, this
additional component could not replace the secondary
pathway of elimination for filgotinib included in the pub-
lished model, with the aim to describe the lower than-
expected observed metabolite exposure (change in OFV of
?33, alternative 2 vs. the publication model).
This suggests that incorporation of a saturable pre-sys-
temic conversion of filgotinib to its active metabolite could
indeed have been a relevant additional component of the
population pharmacokinetic model. However, as
acknowledged by Dr. Srinivas and based on the moderate
improvement in OFV shown above, this would not have
impacted the recommendation for phase IIb dose selection.
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